Comment by
scarlet1967 on Jan 27, 2023 2:54pm
"Audit activities to ensure that Theratechnologies pre-clinical and clinical studies are conducted according to protocols and that any deviation is documented and assessed" THTX isn't involved with any preclinical studies but Sort1!!
Comment by
SABBOBCAT on Jan 27, 2023 3:48pm
Again, if preclinical wasn't sound, you would scrap the program and go back to the drawing board. To me, this reads as if there was lack of governance relating to the trial. Whether that be lack of proper protocols or poor communication or both, who knows. But this does indicate they want to move something forward.
Comment by
stockman75 on Jan 28, 2023 4:20am
Isn't that why we have an overpaid CEO from Pfizer?? I see where Goldman Sachs CEO is receiving a 29 percent pay cut for crappy results. As poorly as THTX has performed I think similar is in order for Thera.
Comment by
qwerty22 on Jan 28, 2023 10:29pm
So every cancer drug that makes it to clinic by definition passes preclinical and only 6% make it to approval so THTX are in the majority. Even passing Ph1 is only 60:40 odds I think. I'm pretty sure many of those fails thought they had som3thing special. Unfortunately I don't think this is completely unsurprising.
Comment by
palinc2000 on Jan 28, 2023 8:40am
Did they identify a flaw in the pre clinical studies which might have led them to erroneous conclusions? Qwerty do you think this is a possibility?
Comment by
ANALIAS00 on Jan 27, 2023 2:54pm
Surprised and Weird that they dont have those skills already... :o(
Comment by
realitycheck4u on Jan 27, 2023 2:55pm
This post has been removed in accordance with Community Policy